The presence of the anti-GITR antibody significantly inhibited the activity of the trimeric GITRL, which provided further evidence that antibodies can interfere with the anti-tumor immune response by blocking the natural TNFSF/TNFRSF signaling pathways [14]. Here, TNFSF18 is linked to neoplasm.